TBX2亚家族基因在非小细胞肺癌中的表达及其与预后的关系  

The expression of TBX2 subfamily in non-small cell lung cancer and its relationship with prognosis

作　　者：米瑞 季源 曹烨[1] 任静 邵赟 浦寻艺 许传先 刘艺[1] 胡志刚 MI Rui;JI Yuan;CAO Ye;REN Jing;SHAO Yun;PU Xunyi;XU Chuanxian;LIU Yi;HU Zhigang(Department of Clinical Laboratory,Wuxi Children′s Hospital/Wuxi Children′s Hospital Affiliated to Nanjing Medical University,Wuxi,Jiangsu 214023,China;School of Medicine,Soochow University,Suzhou,Jiangsu 215123,China)

机构地区：[1]江苏省无锡市儿童医院/南京医科大学附属无锡儿童医院检验科,江苏无锡214023 [2]苏州大学医学院,江苏苏州215123

出　　处：《国际检验医学杂志》2021年第4期405-411,共7页International Journal of Laboratory Medicine

基　　金：江苏省妇幼健康重点人才项目(FRC201741);江苏省无锡市科技发展基金(医疗卫生)项目(WX18ⅡAN027)。

摘　　要：目的分析TBX2亚家族基因在非小细胞肺癌(NSCLC)中的表达及其与预后的关系,对机制进行初步探讨。方法应用生物信息学平台、免疫组织化学染色分析TBX2亚家族基因在NSCLC中的表达及其与预后的关系,分析TBX2亚家族基因间的共表达情况;采用MethHC数据库分析TBX2低表达情况与其基因启动子区域甲基化的关系。结果TBX2亚家族基因在NSCLC组织中的表达水平低于正常肺组织(P<0.05),并与患者的总生存率具有相关性(P<0.05)。MethHC分析显示,TBX2亚家族基因在NSCLC中的基因启动子区域的甲基化程度明显高于正常肺组织(P<0.05)。结论TBX2亚家族基因可能成为NSCLC的新型检测标志物,其低表达是NSCLC预后不良的因素,其低表达现象可能与NSCLC患者启动子区域的甲基化程度增高相关。Objective To analyze the expression of TBX2 subfamily in non-small cell lung cancer(NSCLC),its relationship with prognosis,and initially explored its mechanism.Methods The expression of TBX2 subfamily were analyzed by bioinformatics and immunohistochemistry in NSCLC;the MethHC data base was used to explore the relationship between the low expression of TBX2 and methylation of gene promoter region.Results The expression of TBX2 subfamily in NSCLC was lower than that in normal lung tissue(P<0.05),and was correlated with the overall survival rate of the patients(P<0.05).MethHC analysis showed that the methylation of TBX2 subfamily members in the promoter region of NSCLC was significantly higher than that in normal lung tissues(P<0.05).Conclusion TBX2 subfamily may be a new marker of NSCLC.The low expression of TBX2 subfamily is a poor prognostic factor for NSCLC,which may be related to the increased methylation of promoter region in NSCLC patients.

关 键 词：肺癌 TBX2亚家族 预后 甲基化 

分 类 号：R446.8[医药卫生—诊断学]